Analysts See $-0.02 EPS for Theratechnologies Inc (TH)

September 17, 2017 - By Nellie Frank

 Analysts See $ 0.02 EPS for Theratechnologies Inc (TH)

Investors wait Theratechnologies Inc (TSE:TH) to report on October, 3. its quarterly earnings Wall Street analysts expect $-0.02 earnings per share, down $0.03 or 300.00 % from last year’s $0.01 same quarter earnings. Theratechnologies Inc’s Wall Street analysts see -84.62 % EPS growth, taking into account the $-0.13 EPS reproted in the previous quarter, The stock increased 3.30% or $0.24 on September 15, reaching $7.51. About 124,682 shares traded or 43.58% up from the average. Theratechnologies Inc (TSE:TH) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Theratechnologies Inc. is a specialty pharmaceutical company. The company has market cap of $562.67 million. The Firm addresses medical needs to promote healthy living among human immunodeficiency virus patients. It currently has negative earnings. The Company’s products include EGRIFTA and Ibalizumab.

More important recent Theratechnologies Inc (TSE:TH) news were published by: which released: “Theratechnologies Inc.: Ibalizumab 24-Week Pivotal Phase III Study Results …” on January 18, 2017, also published article titled: “Theratechnologies Regains Rights to EGRIFTA® (tesamorelin for injection) in …”, published: “Theratechnologies Has An Unheralded Blockbuster” on November 15, 2016. More interesting news about Theratechnologies Inc (TSE:TH) was released by: and their article: “Theratechnologies’ (THERF) CEO Luc Tanguay on Q2 2017 Results – Earnings Call …” with publication date: July 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.